Lumiradx [LMDX] - Last Close: $0.0892
Lumiradx is soaring after teaming up with a Big Pharma powerhouse.
The tiny healthcare firm announced a new strategic collaboration with Astrazeneca [AZN] to bring a heart & lung screening hub to England.
The Everton Football Club's community branch will run the effort, which was made possible by an Astrazeneca grant.
The LumiraDx NT-proBNP test is the only NT-proBNP test currently available that can be used with a simple fingerstick sample.
LMDX is leading the premarket with a 332.0% gain in the premarket.
My Take: It doesn't seem like LMDX is actually getting much support from AZN, so I am not sure why the stock is experiencing such a sudden spike. This could be a pump-and-dump in progress, lads, so tread carefully.
Akumin [AKU] - Last Close: $0.1412
Akumin is rallying after... filing for bankruptcy?
Over the weekend, the tiny outpatient diagnostic imaging services company filed for voluntary Chapter 11 bankruptcy.
In the filing, Akumin listed assets ranging from $100 million to $500 million, with liabilities ranging from $1 billion to $10 billion.
The stock is also set to be delisted from the Nasdaq on Oct. 26th, 2023.
The company also announced a deal with Stonepeak that would allow it to become a private company.
AKU is one of this morning's top performers with a 47.4% gain.
My Take: AKU is in bad shape, but it could offer some short-term opportunities in its dying throes. It's not for the faint of heart, but the volatility could be lucrative if you play your cards right.